SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice

Circ Res. 2024 Aug 16;135(5):632-634. doi: 10.1161/CIRCRESAHA.124.324823. Epub 2024 Jul 23.

Justin H Berger^{1

2}, Timothy R Matsuura², Caitlyn E Bowman^{2

3}, Renee Taing², Jiten Patel², Ling Lai², Teresa C Leone², Jeffrey D Reagan⁴, Saptarsi M Haldar⁴, Zoltan Arany², Daniel P Kelly^{1

2}

¹ Division of Cardiology, Cardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA (J.H.B., D.P.K.).
² Department of Medicine, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.H.B., T.R.M., C.E.B., R.T., J.P., L.L., T.C.L., Z.A., D.P.K.).
³ Department of Biology, Williams College, Williamstown, MA (C.E.B.).
⁴ Amgen Research, Cardiometabolic Disorders, South San Francisco, CA (J.D.R., S.M.H.).

No abstract available

Keywords: drug therapy; experimental animal models; heart failure, systolic; ketosis; ventricular remodeling.

Publication types